ArticlePloS one2017
Reprogramming human gallbladder cells into insulin-producing β-like cells.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Small molecules promote the in vitro expansion and passaging of adult mouse pancreatic islets.Biochemistry and biophysics reports · 2026Article
- Stem cell-derived pancreatic beta cells: a step closer to functional diabetes treatment?BMC endocrine disorders · 2025Review
- Engineered extracellular vesicles from human skin cells induce pro-β-cell conversions in pancreatic ductal cells.Advanced nanobiomed research · 2023Article
- Direct reprogramming of human fibroblasts into insulin-producing cells using transcription factors.Communications biology · 2023Article
- Direct Reprogramming of Different Cell Lineages into Pancreatic β-Like Cells.Cellular reprogramming · 2022Review
- Review
- Single-cell transcriptome and accessible chromatin dynamics during endocrine pancreas development.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Overcoming the Limitations of Stem Cell-Derived Beta Cells.Biomolecules · 2022Review
- A Pro-Endocrine Pancreatic Islet Transcriptional Program Established During Development Is Retained in Human Gallbladder Epithelial Cells.Cellular and molecular gastroenterology and hepatology · 2022Article
- Conversion of Gastrointestinal Somatostatin-Expressing D Cells Into Insulin-Producing Beta-Like Cells UponFrontiers in endocrinology · 2022Article
- Targeting β-cell dedifferentiation and transdifferentiation: opportunities and challenges.Endocrine connections · 2021Review
- Molecular mechanisms of transcription factor mediated cell reprogramming: conversion of liver to pancreas.Biochemical Society transactions · 2021Review
- Diabetes Mellitus Is a Chronic Disease that Can Benefit from Therapy with Induced Pluripotent Stem Cells.International journal of molecular sciences · 2020Review
- Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy.Nature reviews. Endocrinology · 2020Review
- Direct Lineage Reprogramming: Harnessing Cell Plasticity between Liver and Pancreas.Cold Spring Harbor perspectives in biology · 2020Review
- Novel Mouse miRNA Chr13_novelMiR7354-5p Improves Bone-Marrow-Derived Mesenchymal Stem Cell Differentiation into Insulin-Producing Cells.Molecular therapy. Nucleic acids · 2020Article
- Insulin-Producing Cell Transplantation Platform for Veterinary Practice.Frontiers in veterinary science · 2020Review
- Reprogramming Cells to Make Insulin.Journal of the Endocrine Society · 2019Review
- Epigenetic and Transcriptome Profiling Identifies a Population of Visceral Adipose-Derived Progenitor Cells with the Potential to Differentiate into an Endocrine Pancreatic Lineage.Cell transplantation · 2019Article
- Pancreas regeneration.Nature · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The gallbladder and cystic duct (GBCs) are parts of the extrahepatic biliary tree and share a common developmental origin with the ventral pancreas. Here, we report on the very first genetic reprogramming of patient-derived human GBCs to β-like cells for potential autologous cell replacement therapy for type 1 diabetes. We developed a robust method for large-scale expansion of human GBCs ex vivo. GBCs were reprogrammed into insulin-producing pancreatic β-like cells by a combined adenoviral-mediated expression of hallmark pancreatic endocrine transcription factors PDX1, MAFA, NEUROG3, and PAX6 and differentiation culture in vitro. The reprogrammed GBCs (rGBCs) strongly induced the production of insulin and pancreatic endocrine genes and these responded to glucose stimulation in vitro. rGBCs also expressed an islet-specific surface marker, which was used to enrich for the most highly reprogrammed cells. More importantly, global mRNA and microRNA expression profiles and protein immunostaining indicated that rGBCs adopted an overall β-like state and these rGBCs engrafted in immunodeficient mice. Furthermore, comparative global expression analyses identified putative regulators of human biliary to β cell fate conversion. In summary, we have developed, for the first time, a reliable and robust genetic reprogramming and culture expansion of primary human GBCs-derived from multiple unrelated donors-into pancreatic β-like cells ex vivo, thus showing that human gallbladder is a potentially rich source of reprogrammable cells for autologous cell therapy in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.